Gene transfer researchers have succeeded – over the course of a single lifetime – in transforming the world’s most persistent and lethal viruses into disease-fighting allies in the quest to improve human health. Now it’s time to do even more.
Human gene therapy is one of the fastest-growing areas of medical research and one of the most promising. The advances made by scientists and clinicians in the field of gene therapy have enabled us to target disease at the genetic level. As gene therapy research moves increasingly into the clinic, we must ensure that our clients are well prepared to safely and confidently manage this new type of research. Through WCG Gene Therapy™, our clients will have access to the best and most current thinking in this new and emerging field.
WCG Gene Therapy combines our unmatched review and consulting capabilities with the insights of experts from diverse backgrounds with specialized knowledge of the clinical development, regulatory oversight, and clinical application of products involving recombinant DNA, to help our clients to safely manage increasing volumes of this complex and potentially hazardous research.
The WCG Gene Therapy Advisory Board provides guidance and strategic counsel to the WIRB-Copernicus Group® (WCG) and its clients, ensuring that knowledge and best practices are reflected in the company’s oversight of human gene transfer research, which involves the careful coordination of institutional review board (IRB) and institutional biosafety committee (IBC) reviews.
The members of the WCG Gene Therapy Advisory Board include:
MARK BAGARAZZI, MD
Chief Medical Officer, Inovio Pharmaceuticals
CARL JUNE, MD
Director of Translational Research, Penn Medicine
HANS-PETER KIEM, MD, Dr med.
Chair, Recombinant DNA Advisory Committee (RAC); Head of Heme Malignancy Program, University of Washington/Fred Hutchinson Cancer Research Center
ARNOLD J. LEVINE, PHD
Professor, Institute for Advanced Study, School of Natural Sciences
TONY REID, MD, PHD
Professor, Department of Medicine, University of California San Diego Health Sciences
WCG has evaluated over 250 human gene transfer protocols to date—more than any organization outside of the Food and Drug Administration (FDA) and the National Institute of Health (NIH). We also maintain a global presence, leading laboratory and biosafety consulting projects in over 50 countries, and operating IBCs in United States and Canada, as well as in Africa, South America, Central America, the Caribbean, and Europe.
WCG Gene Therapy Reggie Scott